Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a diversified biopharmaceutical company, is focused on discovering, developing, and commercializing innovative mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s strategic goal is to discover and develop oral anticancer agents that target the cell cycle with the intent to slow the growth of tumors or even shrink their size while enhancing the patient’s quality of life. For further information, visit the Company’s web site at www.cyclacel.com.
- 17 years ago
QualityStocks
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Launches 12-Month AI-Driven Marketing Campaign With AGORACOM
LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced a 12-month online marketing campaign with…
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Strengthens Balance Sheet with Full Conversion of $13.3 Million Notes
Datavault AI (NASDAQ: DVLT), a pioneer in AI-driven data monetization, announced the full conversion of…
-
Nightfood Holdings Inc. (NGTF) Offering a Portfolio of AI-Powered Robots Designed to Streamline Operations and Enhance Efficiency
Nightfood Holdings has a lineup of AI-powered robots to streamline operations across industries, weaving technology…